LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 4 of total 4

Search options

  1. Article: Promoting local production and active pharmaceutical ingredient (API) industry in low and middle income countries (LMICs): impact on medicines access and policy.

    Khan, Muhammad Akhtar Abbas / Rauf, Asim

    Journal of pharmaceutical policy and practice

    2024  Volume 17, Issue 1, Page(s) 2323683

    Abstract: The success of universal coverage depends on ensuring that patients have access to medicine. Encouraging local production of medicines in developing countries can provide better access to medicines. In addition to determining the quality of ... ...

    Abstract The success of universal coverage depends on ensuring that patients have access to medicine. Encouraging local production of medicines in developing countries can provide better access to medicines. In addition to determining the quality of pharmaceutical goods, Active Pharmaceutical Ingredients (APIs) also determine their cost. According to market forecasts, the active pharmaceutical ingredients market is expected to increase from USD 193.15 billion in 2023 to USD 285.29 billion by 2028. Pakistan largely depends on India and China for its Active Pharmaceutical Ingredient requirements. It was feared that a shortage of medicines would result from Pakistan's government suspending all trade with India on August 9, 2019. To improve health security in Pakistan, the Government of Pakistan has introduced an API promotion Policy in 2022. Financial and non-financial incentives have helped many countries develop their API industries like China, India, and Bangladesh. The current domestic API market of Pakistan is around 150 million $. After the introduction of the policy, the existing units are increasing their capacity while eight new API units are in the process of establishment. Through local production of APIs and intermediates, Pakistan can improve its health security by learning from the experiences of neighbouring countries, especially China.
    Language English
    Publishing date 2024-03-04
    Publishing country England
    Document type Editorial
    ZDB-ID 2734772-2
    ISSN 2052-3211
    ISSN 2052-3211
    DOI 10.1080/20523211.2024.2323683
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Pharmacovigilance in High-Income Countries: Current Developments and a Review of Literature.

    Khan, Muhammad Akhtar Abbas / Hamid, Saima / Babar, Zaheer-Ud-Din

    Pharmacy (Basel, Switzerland)

    2023  Volume 11, Issue 1

    Abstract: The world bank has classified 80 economies based on their Gross National Income (GNI) per capita as High-Income. European Medicines Agency (EMA), Food and Drug Administration (FDA), and Pharmaceuticals and Medical Devices Agency (PMDA) are the major ... ...

    Abstract The world bank has classified 80 economies based on their Gross National Income (GNI) per capita as High-Income. European Medicines Agency (EMA), Food and Drug Administration (FDA), and Pharmaceuticals and Medical Devices Agency (PMDA) are the major regulatory stakeholders driving global pharmacovigilance regulations. The purpose of this article is to describe pharmacovigilance systems and processes in high-income countries, particularly those that are also members of the International Conference on Harmonization (ICH). All high-income countries are members of the WHO PIDM. The income level of a country has a direct relationship with medicine safety measures. All ten pioneering members of the Uppsala monitoring centre are from high-income countries and were the first responders after the thalidomide tragedy by making drug evaluation committees, introducing the ADR reporting forms and taking safety measures. Despite access to the VigiBase, some countries have separate databases for managing and analyzing data like Canada Vigilance online database, FDA Adverse Event Reporting System, the French pharmacovigilance database and European Union's system Eudravigilance. All high-income countries have robust pharmacovigilance systems. USFDA and EMA are the world leaders in the field of pharmacovigilance. Most high-income countries follow EMA guidelines. Medicine safety is directly influenced by a country's income level.
    Language English
    Publishing date 2023-01-06
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2737194-3
    ISSN 2226-4787 ; 2226-4787
    ISSN (online) 2226-4787
    ISSN 2226-4787
    DOI 10.3390/pharmacy11010010
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article: Assessment of the Current State of Pharmacovigilance System in Pakistan Using Indicator-Based Assessment Tool.

    Khan, Muhammad Akhtar Abbas / Hamid, Saima / Ur-Rehman, Tofeeq / Babar, Zaheer-Ud-Din

    Frontiers in pharmacology

    2022  Volume 12, Page(s) 789103

    Abstract: Objectives: ...

    Abstract Objectives:
    Language English
    Publishing date 2022-01-14
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2587355-6
    ISSN 1663-9812
    ISSN 1663-9812
    DOI 10.3389/fphar.2021.789103
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article: A Qualitative Study of Stakeholders' Views on Pharmacovigilance System, Policy, and Coordination in Pakistan.

    Khan, Muhammad Akhtar Abbas / Hamid, Saima / Khan, Shahzad Ali / Sarfraz, Mariyam / Babar, Zaheer-Ud-Din

    Frontiers in pharmacology

    2022  Volume 13, Page(s) 891954

    Abstract: Objectives: ...

    Abstract Objectives:
    Language English
    Publishing date 2022-06-09
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2587355-6
    ISSN 1663-9812
    ISSN 1663-9812
    DOI 10.3389/fphar.2022.891954
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top